Clinical Trial Update: Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI) [Phase 3]

View source ↗

Summary

Open-label Phase 3 assessment of the Albuterol Spiromax dry powder inhaler in patients with asthma and chronic obstructive pulmonary disease, with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Albuterol Spiromax (albuterol)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Asthma, Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Status: COMPLETED | Results posted: 2015-06-08